nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—KIT—myenteric nerve plexus—rectum cancer	0.0253	0.0485	CbGeAlD
Nilotinib—PDGFRA—penis—rectum cancer	0.0179	0.0344	CbGeAlD
Nilotinib—FRK—renal system—rectum cancer	0.00733	0.0141	CbGeAlD
Nilotinib—CDC42BPB—smooth muscle tissue—rectum cancer	0.00642	0.0123	CbGeAlD
Nilotinib—CDC42BPB—renal system—rectum cancer	0.00618	0.0119	CbGeAlD
Nilotinib—CDC42BPB—urethra—rectum cancer	0.00607	0.0117	CbGeAlD
Nilotinib—MAPK8—epithelium—rectum cancer	0.00603	0.0116	CbGeAlD
Nilotinib—FRK—female reproductive system—rectum cancer	0.00587	0.0113	CbGeAlD
Nilotinib—MAPK8—smooth muscle tissue—rectum cancer	0.00581	0.0111	CbGeAlD
Nilotinib—MAPK8—renal system—rectum cancer	0.00559	0.0107	CbGeAlD
Nilotinib—MAPK8—urethra—rectum cancer	0.00549	0.0105	CbGeAlD
Nilotinib—HCK—seminal vesicle—rectum cancer	0.00526	0.0101	CbGeAlD
Nilotinib—TIE1—epithelium—rectum cancer	0.00523	0.01	CbGeAlD
Nilotinib—TIE1—smooth muscle tissue—rectum cancer	0.00504	0.00967	CbGeAlD
Nilotinib—MAPK11—female reproductive system—rectum cancer	0.00499	0.00958	CbGeAlD
Nilotinib—CDC42BPB—female reproductive system—rectum cancer	0.00495	0.0095	CbGeAlD
Nilotinib—TIE1—urethra—rectum cancer	0.00476	0.00914	CbGeAlD
Nilotinib—MAP4K1—mammalian vulva—rectum cancer	0.00475	0.00912	CbGeAlD
Nilotinib—EPHB3—urethra—rectum cancer	0.00453	0.00869	CbGeAlD
Nilotinib—CDC42BPB—vagina—rectum cancer	0.00448	0.0086	CbGeAlD
Nilotinib—MAPK8—female reproductive system—rectum cancer	0.00448	0.0086	CbGeAlD
Nilotinib—EPHA6—female reproductive system—rectum cancer	0.00448	0.0086	CbGeAlD
Nilotinib—FGR—seminal vesicle—rectum cancer	0.00439	0.00842	CbGeAlD
Nilotinib—EPHB3—mammalian vulva—rectum cancer	0.00431	0.00828	CbGeAlD
Nilotinib—CA14—seminal vesicle—rectum cancer	0.00429	0.00823	CbGeAlD
Nilotinib—EPHB4—seminal vesicle—rectum cancer	0.00418	0.00802	CbGeAlD
Nilotinib—HCK—urethra—rectum cancer	0.00416	0.00799	CbGeAlD
Nilotinib—CA7—renal system—rectum cancer	0.00415	0.00796	CbGeAlD
Nilotinib—EPHA2—seminal vesicle—rectum cancer	0.0041	0.00787	CbGeAlD
Nilotinib—MAPK8—vagina—rectum cancer	0.00405	0.00777	CbGeAlD
Nilotinib—HCK—mammalian vulva—rectum cancer	0.00396	0.00761	CbGeAlD
Nilotinib—TIE1—female reproductive system—rectum cancer	0.00388	0.00745	CbGeAlD
Nilotinib—MAPK14—epithelium—rectum cancer	0.00383	0.00735	CbGeAlD
Nilotinib—EPHB6—seminal vesicle—rectum cancer	0.00382	0.00733	CbGeAlD
Nilotinib—EPHA4—urethra—rectum cancer	0.00378	0.00726	CbGeAlD
Nilotinib—EPHB3—female reproductive system—rectum cancer	0.00369	0.00709	CbGeAlD
Nilotinib—MAPK14—smooth muscle tissue—rectum cancer	0.00369	0.00708	CbGeAlD
Nilotinib—MAP4K1—vagina—rectum cancer	0.00368	0.00707	CbGeAlD
Nilotinib—EPHB4—epithelium—rectum cancer	0.00363	0.00697	CbGeAlD
Nilotinib—EPHA4—mammalian vulva—rectum cancer	0.0036	0.00691	CbGeAlD
Nilotinib—EPHA2—epithelium—rectum cancer	0.00356	0.00683	CbGeAlD
Nilotinib—MAPK14—renal system—rectum cancer	0.00355	0.00682	CbGeAlD
Nilotinib—EPHB4—smooth muscle tissue—rectum cancer	0.0035	0.00671	CbGeAlD
Nilotinib—FGR—urethra—rectum cancer	0.00347	0.00667	CbGeAlD
Nilotinib—LCK—urethra—rectum cancer	0.00347	0.00667	CbGeAlD
Nilotinib—TEK—epithelium—rectum cancer	0.00347	0.00667	CbGeAlD
Nilotinib—BRAF—vagina—rectum cancer	0.00337	0.00646	CbGeAlD
Nilotinib—EPHB4—renal system—rectum cancer	0.00337	0.00646	CbGeAlD
Nilotinib—TEK—smooth muscle tissue—rectum cancer	0.00335	0.00642	CbGeAlD
Nilotinib—EPHB3—vagina—rectum cancer	0.00334	0.00641	CbGeAlD
Nilotinib—BLK—lymph node—rectum cancer	0.00331	0.00636	CbGeAlD
Nilotinib—FGR—mammalian vulva—rectum cancer	0.00331	0.00635	CbGeAlD
Nilotinib—LCK—mammalian vulva—rectum cancer	0.00331	0.00635	CbGeAlD
Nilotinib—EPHB4—urethra—rectum cancer	0.00331	0.00635	CbGeAlD
Nilotinib—MAP2K5—seminal vesicle—rectum cancer	0.00327	0.00627	CbGeAlD
Nilotinib—EPHA2—urethra—rectum cancer	0.00324	0.00623	CbGeAlD
Nilotinib—TEK—renal system—rectum cancer	0.00322	0.00618	CbGeAlD
Nilotinib—CSF1R—seminal vesicle—rectum cancer	0.00319	0.00612	CbGeAlD
Nilotinib—TEK—urethra—rectum cancer	0.00316	0.00607	CbGeAlD
Nilotinib—EPHB4—mammalian vulva—rectum cancer	0.00315	0.00604	CbGeAlD
Nilotinib—EPHA2—mammalian vulva—rectum cancer	0.00309	0.00593	CbGeAlD
Nilotinib—EPHA4—female reproductive system—rectum cancer	0.00308	0.00592	CbGeAlD
Nilotinib—HCK—vagina—rectum cancer	0.00307	0.00589	CbGeAlD
Nilotinib—ABL2—vagina—rectum cancer	0.00305	0.00585	CbGeAlD
Nilotinib—PDGFRA—smooth muscle tissue—rectum cancer	0.00303	0.00582	CbGeAlD
Nilotinib—EPHB6—urethra—rectum cancer	0.00302	0.00581	CbGeAlD
Nilotinib—MAPK11—lymph node—rectum cancer	0.00292	0.00561	CbGeAlD
Nilotinib—PDGFRA—renal system—rectum cancer	0.00292	0.0056	CbGeAlD
Nilotinib—CA9—female reproductive system—rectum cancer	0.00292	0.0056	CbGeAlD
Nilotinib—CDC42BPB—lymph node—rectum cancer	0.0029	0.00556	CbGeAlD
Nilotinib—KIT—seminal vesicle—rectum cancer	0.0029	0.00556	CbGeAlD
Nilotinib—EPHB6—mammalian vulva—rectum cancer	0.00288	0.00553	CbGeAlD
Nilotinib—MAPK14—female reproductive system—rectum cancer	0.00284	0.00546	CbGeAlD
Nilotinib—FGR—female reproductive system—rectum cancer	0.00283	0.00544	CbGeAlD
Nilotinib—PDGFRB—seminal vesicle—rectum cancer	0.00283	0.00543	CbGeAlD
Nilotinib—EPHA4—vagina—rectum cancer	0.00279	0.00535	CbGeAlD
Nilotinib—UGT1A1—renal system—rectum cancer	0.00278	0.00534	CbGeAlD
Nilotinib—CA3—vagina—rectum cancer	0.00276	0.00529	CbGeAlD
Nilotinib—EPHA3—lymph node—rectum cancer	0.00275	0.00527	CbGeAlD
Nilotinib—EPHB4—female reproductive system—rectum cancer	0.0027	0.00517	CbGeAlD
Nilotinib—CA12—renal system—rectum cancer	0.00269	0.00517	CbGeAlD
Nilotinib—CSF1R—smooth muscle tissue—rectum cancer	0.00267	0.00512	CbGeAlD
Nilotinib—EPHA2—female reproductive system—rectum cancer	0.00264	0.00508	CbGeAlD
Nilotinib—MAPK8—lymph node—rectum cancer	0.00262	0.00503	CbGeAlD
Nilotinib—MAP2K5—urethra—rectum cancer	0.00259	0.00496	CbGeAlD
Nilotinib—TEK—female reproductive system—rectum cancer	0.00258	0.00495	CbGeAlD
Nilotinib—MAPK14—vagina—rectum cancer	0.00257	0.00494	CbGeAlD
Nilotinib—LCK—vagina—rectum cancer	0.00256	0.00492	CbGeAlD
Nilotinib—FGR—vagina—rectum cancer	0.00256	0.00492	CbGeAlD
Nilotinib—CSF1R—urethra—rectum cancer	0.00252	0.00485	CbGeAlD
Nilotinib—ABL1—seminal vesicle—rectum cancer	0.00252	0.00484	CbGeAlD
Nilotinib—KIT—epithelium—rectum cancer	0.00252	0.00483	CbGeAlD
Nilotinib—MAP2K5—mammalian vulva—rectum cancer	0.00246	0.00473	CbGeAlD
Nilotinib—PDGFRB—epithelium—rectum cancer	0.00246	0.00472	CbGeAlD
Nilotinib—EPHB4—vagina—rectum cancer	0.00244	0.00468	CbGeAlD
Nilotinib—KIT—smooth muscle tissue—rectum cancer	0.00242	0.00465	CbGeAlD
Nilotinib—CSF1R—mammalian vulva—rectum cancer	0.0024	0.00461	CbGeAlD
Nilotinib—EPHA2—vagina—rectum cancer	0.00239	0.00459	CbGeAlD
Nilotinib—MAP4K1—lymph node—rectum cancer	0.00238	0.00457	CbGeAlD
Nilotinib—PDGFRB—smooth muscle tissue—rectum cancer	0.00237	0.00454	CbGeAlD
Nilotinib—PDGFRA—female reproductive system—rectum cancer	0.00234	0.00449	CbGeAlD
Nilotinib—KIT—renal system—rectum cancer	0.00233	0.00448	CbGeAlD
Nilotinib—KIT—urethra—rectum cancer	0.00229	0.0044	CbGeAlD
Nilotinib—PDGFRB—renal system—rectum cancer	0.00228	0.00437	CbGeAlD
Nilotinib—TIE1—lymph node—rectum cancer	0.00227	0.00436	CbGeAlD
Nilotinib—PDGFRB—urethra—rectum cancer	0.00224	0.0043	CbGeAlD
Nilotinib—EPHB6—vagina—rectum cancer	0.00223	0.00428	CbGeAlD
Nilotinib—KIT—mammalian vulva—rectum cancer	0.00218	0.00419	CbGeAlD
Nilotinib—BRAF—lymph node—rectum cancer	0.00218	0.00418	CbGeAlD
Nilotinib—EPHB3—lymph node—rectum cancer	0.00216	0.00415	CbGeAlD
Nilotinib—CA12—female reproductive system—rectum cancer	0.00216	0.00414	CbGeAlD
Nilotinib—CA1—renal system—rectum cancer	0.00213	0.0041	CbGeAlD
Nilotinib—PDGFRB—mammalian vulva—rectum cancer	0.00213	0.00409	CbGeAlD
Nilotinib—PDGFRA—vagina—rectum cancer	0.00211	0.00406	CbGeAlD
Nilotinib—ABL1—smooth muscle tissue—rectum cancer	0.00211	0.00405	CbGeAlD
Nilotinib—MAP2K5—female reproductive system—rectum cancer	0.00211	0.00405	CbGeAlD
Nilotinib—CA4—seminal vesicle—rectum cancer	0.00207	0.00397	CbGeAlD
Nilotinib—CSF1R—female reproductive system—rectum cancer	0.00206	0.00395	CbGeAlD
Nilotinib—ABL1—renal system—rectum cancer	0.00203	0.0039	CbGeAlD
Nilotinib—ABL1—urethra—rectum cancer	0.002	0.00383	CbGeAlD
Nilotinib—HCK—lymph node—rectum cancer	0.00199	0.00381	CbGeAlD
Nilotinib—ABL2—lymph node—rectum cancer	0.00197	0.00379	CbGeAlD
Nilotinib—MAP2K5—vagina—rectum cancer	0.00191	0.00366	CbGeAlD
Nilotinib—ABL1—mammalian vulva—rectum cancer	0.0019	0.00365	CbGeAlD
Nilotinib—KIT—female reproductive system—rectum cancer	0.00187	0.00359	CbGeAlD
Nilotinib—CSF1R—vagina—rectum cancer	0.00186	0.00357	CbGeAlD
Nilotinib—PDGFRB—female reproductive system—rectum cancer	0.00183	0.0035	CbGeAlD
Nilotinib—EPHA4—lymph node—rectum cancer	0.0018	0.00346	CbGeAlD
Nilotinib—CA3—lymph node—rectum cancer	0.00178	0.00342	CbGeAlD
Nilotinib—CA2—seminal vesicle—rectum cancer	0.00172	0.00329	CbGeAlD
Nilotinib—CA1—female reproductive system—rectum cancer	0.00171	0.00328	CbGeAlD
Nilotinib—KIT—vagina—rectum cancer	0.00169	0.00324	CbGeAlD
Nilotinib—CA4—renal system—rectum cancer	0.00167	0.0032	CbGeAlD
Nilotinib—MAPK14—lymph node—rectum cancer	0.00166	0.00319	CbGeAlD
Nilotinib—LCK—lymph node—rectum cancer	0.00166	0.00318	CbGeAlD
Nilotinib—FGR—lymph node—rectum cancer	0.00166	0.00318	CbGeAlD
Nilotinib—PDGFRB—vagina—rectum cancer	0.00165	0.00317	CbGeAlD
Nilotinib—CA4—urethra—rectum cancer	0.00164	0.00315	CbGeAlD
Nilotinib—ABL1—female reproductive system—rectum cancer	0.00163	0.00312	CbGeAlD
Nilotinib—ABCG2—seminal vesicle—rectum cancer	0.00159	0.00305	CbGeAlD
Nilotinib—EPHB4—lymph node—rectum cancer	0.00158	0.00303	CbGeAlD
Nilotinib—EPHA2—lymph node—rectum cancer	0.00155	0.00297	CbGeAlD
Nilotinib—TEK—lymph node—rectum cancer	0.00151	0.0029	CbGeAlD
Nilotinib—CA2—epithelium—rectum cancer	0.00149	0.00286	CbGeAlD
Nilotinib—ABL1—vagina—rectum cancer	0.00147	0.00282	CbGeAlD
Nilotinib—EPHB6—lymph node—rectum cancer	0.00144	0.00277	CbGeAlD
Nilotinib—CA2—smooth muscle tissue—rectum cancer	0.00144	0.00276	CbGeAlD
Nilotinib—CA2—renal system—rectum cancer	0.00138	0.00265	CbGeAlD
Nilotinib—PDGFRA—lymph node—rectum cancer	0.00137	0.00262	CbGeAlD
Nilotinib—CA4—female reproductive system—rectum cancer	0.00134	0.00256	CbGeAlD
Nilotinib—CYP2C8—renal system—rectum cancer	0.00132	0.00253	CbGeAlD
Nilotinib—CA2—mammalian vulva—rectum cancer	0.00129	0.00248	CbGeAlD
Nilotinib—ABCG2—urethra—rectum cancer	0.00126	0.00242	CbGeAlD
Nilotinib—MAP2K5—lymph node—rectum cancer	0.00123	0.00237	CbGeAlD
Nilotinib—CSF1R—lymph node—rectum cancer	0.0012	0.00231	CbGeAlD
Nilotinib—ABCG2—mammalian vulva—rectum cancer	0.0012	0.0023	CbGeAlD
Nilotinib—CYP2B6—renal system—rectum cancer	0.00118	0.00227	CbGeAlD
Nilotinib—CA2—female reproductive system—rectum cancer	0.00111	0.00213	CbGeAlD
Nilotinib—KIT—lymph node—rectum cancer	0.00109	0.0021	CbGeAlD
Nilotinib—PDGFRB—lymph node—rectum cancer	0.00107	0.00205	CbGeAlD
Nilotinib—CYP2C8—female reproductive system—rectum cancer	0.00106	0.00203	CbGeAlD
Nilotinib—CA2—vagina—rectum cancer	0.001	0.00192	CbGeAlD
Nilotinib—CA1—lymph node—rectum cancer	0.001	0.00192	CbGeAlD
Nilotinib—CYP2C8—vagina—rectum cancer	0.000954	0.00183	CbGeAlD
Nilotinib—ABL1—lymph node—rectum cancer	0.000952	0.00183	CbGeAlD
Nilotinib—CYP2B6—female reproductive system—rectum cancer	0.000946	0.00182	CbGeAlD
Nilotinib—CYP2C9—female reproductive system—rectum cancer	0.000937	0.0018	CbGeAlD
Nilotinib—ABCG2—vagina—rectum cancer	0.000928	0.00178	CbGeAlD
Nilotinib—CYP3A4—renal system—rectum cancer	0.000892	0.00171	CbGeAlD
Nilotinib—CYP2D6—renal system—rectum cancer	0.000878	0.00169	CbGeAlD
Nilotinib—CYP2B6—vagina—rectum cancer	0.000856	0.00164	CbGeAlD
Nilotinib—ABCB1—seminal vesicle—rectum cancer	0.000784	0.0015	CbGeAlD
Nilotinib—CA4—lymph node—rectum cancer	0.000781	0.0015	CbGeAlD
Nilotinib—CYP3A4—female reproductive system—rectum cancer	0.000715	0.00137	CbGeAlD
Nilotinib—CYP2D6—female reproductive system—rectum cancer	0.000703	0.00135	CbGeAlD
Nilotinib—ABCB1—epithelium—rectum cancer	0.000681	0.00131	CbGeAlD
Nilotinib—CA2—lymph node—rectum cancer	0.000648	0.00124	CbGeAlD
Nilotinib—ABCB1—renal system—rectum cancer	0.000632	0.00121	CbGeAlD
Nilotinib—ABCB1—urethra—rectum cancer	0.00062	0.00119	CbGeAlD
Nilotinib—ABCG2—lymph node—rectum cancer	0.0006	0.00115	CbGeAlD
Nilotinib—ABCB1—mammalian vulva—rectum cancer	0.000591	0.00113	CbGeAlD
Nilotinib—ABCB1—female reproductive system—rectum cancer	0.000506	0.000971	CbGeAlD
Nilotinib—ABCB1—vagina—rectum cancer	0.000457	0.000878	CbGeAlD
Nilotinib—ABCB1—lymph node—rectum cancer	0.000296	0.000568	CbGeAlD
Nilotinib—LCK—Signaling by SCF-KIT—HRAS—rectum cancer	0.000161	0.000337	CbGpPWpGaD
Nilotinib—FGR—Hemostasis—NRAS—rectum cancer	0.000161	0.000336	CbGpPWpGaD
Nilotinib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—rectum cancer	0.000161	0.000336	CbGpPWpGaD
Nilotinib—HCK—Innate Immune System—NRAS—rectum cancer	0.00016	0.000335	CbGpPWpGaD
Nilotinib—PDGFRB—Focal Adhesion—HRAS—rectum cancer	0.000158	0.000331	CbGpPWpGaD
Nilotinib—EPHA2—Developmental Biology—HRAS—rectum cancer	0.000158	0.000331	CbGpPWpGaD
Nilotinib—LCK—Signaling by FGFR in disease—KRAS—rectum cancer	0.000158	0.00033	CbGpPWpGaD
Nilotinib—LCK—DAP12 interactions—KRAS—rectum cancer	0.000158	0.00033	CbGpPWpGaD
Nilotinib—LCK—Fc epsilon receptor (FCERI) signaling—KRAS—rectum cancer	0.000158	0.00033	CbGpPWpGaD
Nilotinib—KIT—Signaling by NGF—KRAS—rectum cancer	0.000158	0.000329	CbGpPWpGaD
Nilotinib—LCK—Signaling by EGFR—KRAS—rectum cancer	0.000157	0.000328	CbGpPWpGaD
Nilotinib—MAPK14—Cellular Senescence—TP53—rectum cancer	0.000156	0.000326	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by NGF—NRAS—rectum cancer	0.000156	0.000326	CbGpPWpGaD
Nilotinib—LCK—Signaling by EGFR in Cancer—KRAS—rectum cancer	0.000155	0.000325	CbGpPWpGaD
Nilotinib—LYN—Cytokine Signaling in Immune system—NRAS—rectum cancer	0.000155	0.000325	CbGpPWpGaD
Nilotinib—PDGFRB—B Cell Activation—HRAS—rectum cancer	0.000155	0.000324	CbGpPWpGaD
Nilotinib—LCK—Signaling by PDGF—KRAS—rectum cancer	0.000155	0.000323	CbGpPWpGaD
Nilotinib—LCK—Downstream signaling of activated FGFR—HRAS—rectum cancer	0.000154	0.000322	CbGpPWpGaD
Nilotinib—MAPK14—Integrated Pancreatic Cancer Pathway—TP53—rectum cancer	0.000153	0.00032	CbGpPWpGaD
Nilotinib—LCK—Signaling by ERBB4—HRAS—rectum cancer	0.000152	0.000317	CbGpPWpGaD
Nilotinib—LYN—B Cell Activation—HRAS—rectum cancer	0.000152	0.000317	CbGpPWpGaD
Nilotinib—BRAF—Neuronal System—HRAS—rectum cancer	0.00015	0.000313	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by NGF—KRAS—rectum cancer	0.000149	0.000311	CbGpPWpGaD
Nilotinib—MAPK11—Signaling by NGF—HRAS—rectum cancer	0.000149	0.00031	CbGpPWpGaD
Nilotinib—PDGFRB—NGF signalling via TRKA from the plasma membrane—HRAS—rectum cancer	0.000149	0.00031	CbGpPWpGaD
Nilotinib—BRAF—Signaling by NGF—HRAS—rectum cancer	0.000147	0.000307	CbGpPWpGaD
Nilotinib—LCK—B Cell Activation—KRAS—rectum cancer	0.000147	0.000306	CbGpPWpGaD
Nilotinib—MAPK8—Innate Immune System—NRAS—rectum cancer	0.000145	0.000303	CbGpPWpGaD
Nilotinib—LCK—Downstream signal transduction—HRAS—rectum cancer	0.000145	0.000303	CbGpPWpGaD
Nilotinib—MAPK14—Signaling by NGF—NRAS—rectum cancer	0.000145	0.000303	CbGpPWpGaD
Nilotinib—FGR—Innate Immune System—NRAS—rectum cancer	0.000145	0.000302	CbGpPWpGaD
Nilotinib—LCK—Signaling by FGFR—HRAS—rectum cancer	0.000144	0.000302	CbGpPWpGaD
Nilotinib—LCK—Signaling by ERBB2—HRAS—rectum cancer	0.000144	0.0003	CbGpPWpGaD
Nilotinib—LCK—DAP12 signaling—HRAS—rectum cancer	0.000143	0.000299	CbGpPWpGaD
Nilotinib—CA9—Metabolism—TYMS—rectum cancer	0.000142	0.000297	CbGpPWpGaD
Nilotinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—HRAS—rectum cancer	0.000141	0.000294	CbGpPWpGaD
Nilotinib—LCK—NGF signalling via TRKA from the plasma membrane—KRAS—rectum cancer	0.00014	0.000293	CbGpPWpGaD
Nilotinib—BLK—Adaptive Immune System—NRAS—rectum cancer	0.00014	0.000291	CbGpPWpGaD
Nilotinib—FGR—Hemostasis—KRAS—rectum cancer	0.000138	0.000289	CbGpPWpGaD
Nilotinib—LYN—Axon guidance—NRAS—rectum cancer	0.000138	0.000289	CbGpPWpGaD
Nilotinib—HCK—Innate Immune System—KRAS—rectum cancer	0.000138	0.000288	CbGpPWpGaD
Nilotinib—MAPK14—NGF signalling via TRKA from the plasma membrane—HRAS—rectum cancer	0.000138	0.000288	CbGpPWpGaD
Nilotinib—ABL1—Axon guidance—NRAS—rectum cancer	0.000138	0.000287	CbGpPWpGaD
Nilotinib—LCK—DAP12 interactions—HRAS—rectum cancer	0.000135	0.000281	CbGpPWpGaD
Nilotinib—LCK—Fc epsilon receptor (FCERI) signaling—HRAS—rectum cancer	0.000135	0.000281	CbGpPWpGaD
Nilotinib—LCK—Signaling by FGFR in disease—HRAS—rectum cancer	0.000135	0.000281	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by NGF—KRAS—rectum cancer	0.000134	0.000281	CbGpPWpGaD
Nilotinib—KIT—Signaling by NGF—HRAS—rectum cancer	0.000134	0.00028	CbGpPWpGaD
Nilotinib—LYN—Cytokine Signaling in Immune system—KRAS—rectum cancer	0.000134	0.000279	CbGpPWpGaD
Nilotinib—LCK—Signaling by EGFR—HRAS—rectum cancer	0.000133	0.000278	CbGpPWpGaD
Nilotinib—LCK—Signaling by EGFR in Cancer—HRAS—rectum cancer	0.000132	0.000276	CbGpPWpGaD
Nilotinib—LCK—Signaling by PDGF—HRAS—rectum cancer	0.000132	0.000275	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—NRAS—rectum cancer	0.000131	0.000274	CbGpPWpGaD
Nilotinib—LCK—Cytokine Signaling in Immune system—NRAS—rectum cancer	0.000127	0.000266	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by NGF—HRAS—rectum cancer	0.000127	0.000265	CbGpPWpGaD
Nilotinib—LCK—Signaling by NGF—NRAS—rectum cancer	0.000125	0.000262	CbGpPWpGaD
Nilotinib—MAPK8—Innate Immune System—KRAS—rectum cancer	0.000125	0.000261	CbGpPWpGaD
Nilotinib—MAPK14—Signaling by NGF—KRAS—rectum cancer	0.000125	0.00026	CbGpPWpGaD
Nilotinib—FGR—Innate Immune System—KRAS—rectum cancer	0.000125	0.00026	CbGpPWpGaD
Nilotinib—LCK—B Cell Activation—HRAS—rectum cancer	0.000125	0.00026	CbGpPWpGaD
Nilotinib—FGR—Hemostasis—TP53—rectum cancer	0.000123	0.000257	CbGpPWpGaD
Nilotinib—BLK—Adaptive Immune System—KRAS—rectum cancer	0.00012	0.000251	CbGpPWpGaD
Nilotinib—LCK—NGF signalling via TRKA from the plasma membrane—HRAS—rectum cancer	0.000119	0.000249	CbGpPWpGaD
Nilotinib—LYN—Axon guidance—KRAS—rectum cancer	0.000119	0.000249	CbGpPWpGaD
Nilotinib—ABL1—Axon guidance—KRAS—rectum cancer	0.000119	0.000247	CbGpPWpGaD
Nilotinib—MAPK14—Cellular responses to stress—TP53—rectum cancer	0.000118	0.000247	CbGpPWpGaD
Nilotinib—FGR—Hemostasis—HRAS—rectum cancer	0.000118	0.000246	CbGpPWpGaD
Nilotinib—HCK—Innate Immune System—HRAS—rectum cancer	0.000117	0.000245	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—NRAS—rectum cancer	0.000116	0.000242	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by NGF—HRAS—rectum cancer	0.000114	0.000238	CbGpPWpGaD
Nilotinib—LYN—Cytokine Signaling in Immune system—HRAS—rectum cancer	0.000114	0.000237	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—KRAS—rectum cancer	0.000113	0.000236	CbGpPWpGaD
Nilotinib—LCK—Cytokine Signaling in Immune system—KRAS—rectum cancer	0.00011	0.000229	CbGpPWpGaD
Nilotinib—LCK—Signaling by NGF—KRAS—rectum cancer	0.000108	0.000225	CbGpPWpGaD
Nilotinib—MAPK8—Innate Immune System—HRAS—rectum cancer	0.000106	0.000222	CbGpPWpGaD
Nilotinib—MAPK14—Signaling by NGF—HRAS—rectum cancer	0.000106	0.000221	CbGpPWpGaD
Nilotinib—FGR—Innate Immune System—HRAS—rectum cancer	0.000106	0.000221	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—NRAS—rectum cancer	0.000104	0.000218	CbGpPWpGaD
Nilotinib—BLK—Adaptive Immune System—HRAS—rectum cancer	0.000102	0.000213	CbGpPWpGaD
Nilotinib—LYN—Axon guidance—HRAS—rectum cancer	0.000101	0.000211	CbGpPWpGaD
Nilotinib—ABL1—Axon guidance—HRAS—rectum cancer	0.000101	0.00021	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—NRAS—rectum cancer	0.0001	0.000209	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—KRAS—rectum cancer	9.97e-05	0.000208	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—NRAS—rectum cancer	9.88e-05	0.000206	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—NRAS—rectum cancer	9.87e-05	0.000206	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—NRAS—rectum cancer	9.83e-05	0.000205	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—NRAS—rectum cancer	9.68e-05	0.000202	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—NRAS—rectum cancer	9.64e-05	0.000201	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—HRAS—rectum cancer	9.59e-05	0.0002	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—NRAS—rectum cancer	9.49e-05	0.000198	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—NRAS—rectum cancer	9.36e-05	0.000195	CbGpPWpGaD
Nilotinib—HCK—Immune System—NRAS—rectum cancer	9.34e-05	0.000195	CbGpPWpGaD
Nilotinib—LCK—Cytokine Signaling in Immune system—HRAS—rectum cancer	9.32e-05	0.000195	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—NRAS—rectum cancer	9.18e-05	0.000192	CbGpPWpGaD
Nilotinib—LCK—Signaling by NGF—HRAS—rectum cancer	9.17e-05	0.000191	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—KRAS—rectum cancer	8.99e-05	0.000188	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—NRAS—rectum cancer	8.91e-05	0.000186	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—NRAS—rectum cancer	8.72e-05	0.000182	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—NRAS—rectum cancer	8.68e-05	0.000181	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—KRAS—rectum cancer	8.63e-05	0.00018	CbGpPWpGaD
Nilotinib—HCK—Disease—NRAS—rectum cancer	8.63e-05	0.00018	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—NRAS—rectum cancer	8.55e-05	0.000179	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—KRAS—rectum cancer	8.51e-05	0.000178	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—KRAS—rectum cancer	8.5e-05	0.000177	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—TYMS—rectum cancer	8.47e-05	0.000177	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—HRAS—rectum cancer	8.47e-05	0.000177	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—NRAS—rectum cancer	8.47e-05	0.000177	CbGpPWpGaD
Nilotinib—BLK—Immune System—NRAS—rectum cancer	8.47e-05	0.000177	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—KRAS—rectum cancer	8.46e-05	0.000177	CbGpPWpGaD
Nilotinib—FGR—Immune System—NRAS—rectum cancer	8.44e-05	0.000176	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—NRAS—rectum cancer	8.37e-05	0.000175	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—KRAS—rectum cancer	8.34e-05	0.000174	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—KRAS—rectum cancer	8.3e-05	0.000173	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—NRAS—rectum cancer	8.27e-05	0.000173	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—KRAS—rectum cancer	8.17e-05	0.000171	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—KRAS—rectum cancer	8.05e-05	0.000168	CbGpPWpGaD
Nilotinib—HCK—Immune System—KRAS—rectum cancer	8.04e-05	0.000168	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—NRAS—rectum cancer	7.94e-05	0.000166	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—KRAS—rectum cancer	7.9e-05	0.000165	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—rectum cancer	7.8e-05	0.000163	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—KRAS—rectum cancer	7.66e-05	0.00016	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—HRAS—rectum cancer	7.64e-05	0.000159	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—KRAS—rectum cancer	7.5e-05	0.000157	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—KRAS—rectum cancer	7.47e-05	0.000156	CbGpPWpGaD
Nilotinib—HCK—Disease—KRAS—rectum cancer	7.42e-05	0.000155	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—TP53—rectum cancer	7.41e-05	0.000155	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—TP53—rectum cancer	7.37e-05	0.000154	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—KRAS—rectum cancer	7.36e-05	0.000154	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—HRAS—rectum cancer	7.34e-05	0.000153	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—KRAS—rectum cancer	7.29e-05	0.000152	CbGpPWpGaD
Nilotinib—BLK—Immune System—KRAS—rectum cancer	7.29e-05	0.000152	CbGpPWpGaD
Nilotinib—FGR—Immune System—KRAS—rectum cancer	7.26e-05	0.000152	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—HRAS—rectum cancer	7.23e-05	0.000151	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—HRAS—rectum cancer	7.22e-05	0.000151	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—KRAS—rectum cancer	7.21e-05	0.00015	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—TYMS—rectum cancer	7.19e-05	0.00015	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—HRAS—rectum cancer	7.19e-05	0.00015	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—NRAS—rectum cancer	7.15e-05	0.000149	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—KRAS—rectum cancer	7.11e-05	0.000149	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—HRAS—rectum cancer	7.08e-05	0.000148	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—HRAS—rectum cancer	7.05e-05	0.000147	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—TP53—rectum cancer	7.02e-05	0.000147	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—HRAS—rectum cancer	6.94e-05	0.000145	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—rectum cancer	6.93e-05	0.000145	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—NRAS—rectum cancer	6.86e-05	0.000143	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—HRAS—rectum cancer	6.85e-05	0.000143	CbGpPWpGaD
Nilotinib—HCK—Immune System—HRAS—rectum cancer	6.84e-05	0.000143	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—KRAS—rectum cancer	6.83e-05	0.000143	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—NRAS—rectum cancer	6.75e-05	0.000141	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—HRAS—rectum cancer	6.72e-05	0.00014	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—HRAS—rectum cancer	6.51e-05	0.000136	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—HRAS—rectum cancer	6.38e-05	0.000133	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—HRAS—rectum cancer	6.35e-05	0.000133	CbGpPWpGaD
Nilotinib—HCK—Disease—HRAS—rectum cancer	6.31e-05	0.000132	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—HRAS—rectum cancer	6.26e-05	0.000131	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—HRAS—rectum cancer	6.19e-05	0.000129	CbGpPWpGaD
Nilotinib—BLK—Immune System—HRAS—rectum cancer	6.19e-05	0.000129	CbGpPWpGaD
Nilotinib—FGR—Immune System—HRAS—rectum cancer	6.17e-05	0.000129	CbGpPWpGaD
Nilotinib—BRAF—Disease—NRAS—rectum cancer	6.17e-05	0.000129	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—KRAS—rectum cancer	6.15e-05	0.000128	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—HRAS—rectum cancer	6.12e-05	0.000128	CbGpPWpGaD
Nilotinib—KIT—Immune System—NRAS—rectum cancer	6.08e-05	0.000127	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—TP53—rectum cancer	6.07e-05	0.000127	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—HRAS—rectum cancer	6.05e-05	0.000126	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—KRAS—rectum cancer	5.91e-05	0.000123	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—HRAS—rectum cancer	5.81e-05	0.000121	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—KRAS—rectum cancer	5.81e-05	0.000121	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—NRAS—rectum cancer	5.76e-05	0.00012	CbGpPWpGaD
Nilotinib—KIT—Disease—NRAS—rectum cancer	5.62e-05	0.000117	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—NRAS—rectum cancer	5.47e-05	0.000114	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—NRAS—rectum cancer	5.32e-05	0.000111	CbGpPWpGaD
Nilotinib—BRAF—Disease—KRAS—rectum cancer	5.31e-05	0.000111	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—TYMS—rectum cancer	5.27e-05	0.00011	CbGpPWpGaD
Nilotinib—KIT—Immune System—KRAS—rectum cancer	5.23e-05	0.000109	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—HRAS—rectum cancer	5.23e-05	0.000109	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—NRAS—rectum cancer	5.2e-05	0.000109	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—NRAS—rectum cancer	5.19e-05	0.000108	CbGpPWpGaD
Nilotinib—LYN—Immune System—NRAS—rectum cancer	5.08e-05	0.000106	CbGpPWpGaD
Nilotinib—ABL1—Immune System—NRAS—rectum cancer	5.05e-05	0.000106	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—HRAS—rectum cancer	5.02e-05	0.000105	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—KRAS—rectum cancer	4.96e-05	0.000103	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—HRAS—rectum cancer	4.93e-05	0.000103	CbGpPWpGaD
Nilotinib—KIT—Disease—KRAS—rectum cancer	4.83e-05	0.000101	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—NRAS—rectum cancer	4.81e-05	0.0001	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—NRAS—rectum cancer	4.79e-05	0.0001	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—KRAS—rectum cancer	4.71e-05	9.83e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—KRAS—rectum cancer	4.57e-05	9.55e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—HRAS—rectum cancer	4.51e-05	9.42e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—KRAS—rectum cancer	4.48e-05	9.35e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—KRAS—rectum cancer	4.46e-05	9.32e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—TYMS—rectum cancer	4.46e-05	9.32e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—HRAS—rectum cancer	4.45e-05	9.29e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—KRAS—rectum cancer	4.37e-05	9.12e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—NRAS—rectum cancer	4.36e-05	9.1e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—KRAS—rectum cancer	4.35e-05	9.08e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—NRAS—rectum cancer	4.32e-05	9.02e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—HRAS—rectum cancer	4.21e-05	8.79e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TP53—rectum cancer	4.19e-05	8.74e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—NRAS—rectum cancer	4.16e-05	8.69e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—KRAS—rectum cancer	4.14e-05	8.65e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—KRAS—rectum cancer	4.12e-05	8.6e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—HRAS—rectum cancer	4.11e-05	8.58e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—HRAS—rectum cancer	4e-05	8.36e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—rectum cancer	3.98e-05	8.31e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—NRAS—rectum cancer	3.93e-05	8.21e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—HRAS—rectum cancer	3.89e-05	8.12e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—TYMS—rectum cancer	3.89e-05	8.12e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—NRAS—rectum cancer	3.84e-05	8.02e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—HRAS—rectum cancer	3.81e-05	7.95e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—HRAS—rectum cancer	3.79e-05	7.92e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—KRAS—rectum cancer	3.75e-05	7.84e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NRAS—rectum cancer	3.72e-05	7.77e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—KRAS—rectum cancer	3.72e-05	7.76e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—HRAS—rectum cancer	3.72e-05	7.76e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—HRAS—rectum cancer	3.7e-05	7.72e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—TYMS—rectum cancer	3.66e-05	7.65e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—TYMS—rectum cancer	3.63e-05	7.58e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—KRAS—rectum cancer	3.58e-05	7.48e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—HRAS—rectum cancer	3.52e-05	7.35e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—HRAS—rectum cancer	3.5e-05	7.31e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—KRAS—rectum cancer	3.38e-05	7.07e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NRAS—rectum cancer	3.35e-05	7e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—rectum cancer	3.34e-05	6.96e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—KRAS—rectum cancer	3.31e-05	6.9e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—rectum cancer	3.3e-05	6.9e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NRAS—rectum cancer	3.28e-05	6.85e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—KRAS—rectum cancer	3.2e-05	6.69e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—HRAS—rectum cancer	3.19e-05	6.66e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—HRAS—rectum cancer	3.16e-05	6.6e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NRAS—rectum cancer	3.11e-05	6.5e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—HRAS—rectum cancer	3.05e-05	6.36e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—rectum cancer	3.01e-05	6.28e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—KRAS—rectum cancer	2.89e-05	6.03e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—HRAS—rectum cancer	2.88e-05	6.01e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—rectum cancer	2.85e-05	5.94e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—KRAS—rectum cancer	2.83e-05	5.9e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—HRAS—rectum cancer	2.81e-05	5.87e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—HRAS—rectum cancer	2.72e-05	5.68e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NRAS—rectum cancer	2.69e-05	5.62e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—KRAS—rectum cancer	2.68e-05	5.59e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—rectum cancer	2.57e-05	5.35e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—rectum cancer	2.51e-05	5.24e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—HRAS—rectum cancer	2.45e-05	5.12e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—HRAS—rectum cancer	2.4e-05	5.01e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—TYMS—rectum cancer	2.4e-05	5e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—rectum cancer	2.38e-05	4.97e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KRAS—rectum cancer	2.32e-05	4.84e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—HRAS—rectum cancer	2.28e-05	4.75e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—rectum cancer	2.06e-05	4.3e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HRAS—rectum cancer	1.97e-05	4.11e-05	CbGpPWpGaD
